Latest News - IDEXX Laboratories
Top Corporates Hub
IDEXX Laboratories
Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories
30.09.2026 13:00
Chicago Pacific Founders ("CPF") today announced the exit of its investment in CoVetAI Inc. ("CoVet") following the company's acquisition by IDEXX Laboratories, Inc. (NASDAQ: IDXX). Financial terms were not disclosed.
Companion Animal Diagnostic Market Forecasts Growth from $3.56B (2026) to $5.40B by 2031, Profiling IDEXX Laboratories & Zoetis
24.09.2026 10:19
The companion animal diagnostics market is projected to grow from USD 3.56 billion in 2026 to USD 5.40 billion by 2031, registering an 8.7% CAGR. Growth is driven by rising pet healthcare spending, preventive care, chronic and infectious diseases, and advances in AI, molecular diagnostics, point-of-care testing and automated analyzers. Molecular diagnostics will record the fastest growth, while consumables remain the leading product segment. Asia Pacific is expected to be the fastest-growing reg
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets
20.09.2026 15:02
IDEXX Laboratories (NASDAQ:IDXX) executives highlighted the company’s diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure
IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference
20.09.2026 14:02
IDEXX Laboratories (NASDAQ:IDXX) executives reiterated the company’s long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers. Chief Executive Of
IDEXX (IDXX) Stock Trades Below Fair Value Following Its 26% Slide
18.09.2026 03:15
IDEXX Laboratories has seen a mixed share price story in recent years, and the question now is whether its current US$506.48 level lines up with the cash flows the business may generate over time. Recent price pressure and fresh AI-driven software ambitions are pulling investor attention back to a simple issue: what are those cash flows worth today? Over the past 5 years the stock has delivered a decline of 25.8%, which puts the focus squarely on whether the cash flow outlook still supports...
IDEXX (IDXX) Stock Trades Below Fair Value Following Its 26% Slide
18.09.2026 03:15
IDEXX Laboratories has seen a mixed share price story in recent years, and the question now is whether its current US$506.48 level lines up with the cash flows the business may generate over time. Recent price pressure and fresh AI-driven software ambitions are pulling investor attention back to a simple issue: what are those cash flows worth today? Over the past 5 years the stock has delivered a decline of 25.8%, which puts the focus squarely on whether the cash flow outlook still supports...
Is IDEXX’s Expanded Zoonosis Testing Menu Altering The Investment Case For IDEXX Laboratories (IDXX)?
17.09.2026 11:11
IDEXX Laboratories recently expanded its Faecal Dx antigen testing platform in the United Kingdom to include taeniid tapeworm detection, broadening routine intestinal parasite screening to seven clinically relevant parasite groups and triggering automatic, complimentary Echinococcus RealPCR follow-up tests for positive cases. This expansion deepens the clinical scope and perceived value of Faecal Dx, which has already been used in more than 50 million tests globally since 2012, potentially...
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
17.09.2026 07:00
WESTBROOK, Maine, September 17, 2026--IDEXX expands Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
16.09.2026 11:00
WESTBROOK, Maine, September 16, 2026--IDEXX announces acquisition of CoVetAI to advance veterinary workflow intelligence.
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
16.09.2026 11:00
WESTBROOK, Maine, September 16, 2026--IDEXX announces acquisition of CoVetAI to advance veterinary workflow intelligence.
Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock
10.09.2026 11:20
Kingsley exercised options at $114.17 per share before immediately selling at $532.08, capturing a significant gain. His direct stake remains at 9,568 shares worth $5.12 million.
Baron Partners Fund Q2 2026 Contributors And Detractors
10.09.2026 10:15
Top contributors include Space Exploration Technologies, Tesla, Red Rock Resorts, Hyatt Hotels and Birkenstock Holding. Read more here.
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day - Slideshow
14.08.2026 13:34
2026-08-14. The following slide deck was published by IDEXX Laboratories, Inc.
Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?
13.08.2026 02:10
IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected veterinary diagnostics portfolio and tapping into an underassessed companion-animal heart disease market. We’ll now examine how the new Catalyst proBNP Test and...
Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $710
11.08.2026 09:51
Barclays analyst Glen Santangelo maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $800 to $710.
IDEXX Laboratories: Worth The Premium
08.08.2026 08:00
IDEXX Labs remains a buy: durable moat, recurring revenue, raised FY26 EPS outlook, and long-term international growth. Click to see Q2 highlights & valuation.
IDEXX Laboratories Q2 Earnings Call Highlights
04.08.2026 16:04
IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock, poultry and dairy businesses. The company raised its full-year revenue and earnings outlook, citing s
IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market
04.08.2026 15:50
IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.
Idexx (IDXX) Reports Q2 Earnings: What Key Metrics Have to Say
04.08.2026 13:30
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.